StreetInsider.com News Articles

Form 4 Zoetis Inc. For: Sep 30 Filed by: FULLER JULIE

Fri, 02 Oct 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20261002/27143073.html

KeyBanc Reiterates Overweight Rating on Elanco Animal Health (ELAN)

Wed, 30 Sep 2026 08:47:17 -0400

KeyBanc analyst Steve Dechert reiterated an Overweight rating and $30.00 price target on Elanco Animal Health (NYSE: ELAN).

The analyst commented: "We ran a survey in mid-September that went out to 50 vet clinics in the U.S. Responses suggest that broad-spectrum parasiticides remain healthier than derm, with 64% of clinics prescribing more vs. last year. Competitive pressure on ZTS's Simparica Trio appears primarily economic, supporting ZTS's gross-to-net strategy. However, Apoquel faces more clinically driven pressure, while Cytopoint appears more resilient, with affordability the primary concern. For ELAN, Quattro and Zenrelia adoption trends remain strong and are largely efficacy-driven, supporting continued share-gain

KeyBanc Reiterates Overweight Rating on Elanco Animal Health (ELAN)

Wed, 30 Sep 2026 08:47:17 -0400

KeyBanc analyst Steve Dechert reiterated an Overweight rating and $30.00 price target on Elanco Animal Health (NYSE: ELAN).

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

Thu, 24 Sep 2026 07:30:00 -0400

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts.

Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on November 5,

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

Thu, 24 Sep 2026 07:30:00 -0400

Form 4 Zoetis Inc. For: Sep 17 Filed by: Stetter Mark

Fri, 18 Sep 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260918/27081405.html

Zoetis (ZTS) Reiterated at Hold by Stifel - AD mAb Share Losses Ahead

Fri, 18 Sep 2026 07:57:07 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $80.00 price target on Zoetis Inc. (NYSE: ZTS).

The analyst commented, "For Zoetis, we see no evidence that recent price actions have stabilized AD JAK share and future AD mAb share losses appear on the horizon. While the company seems comfortable with their revised guidance for 2026, our findings are supportive of our Street-low 2027 estimates (revenue and EPS). On a more upbeat note, 2028+ shows some signs of promise as Zoetis’ (and Elanco’s) product pipelines align with the Vets’ wish lists, but 2028 feels far away in an ongoing difficult Animal

Form 4 Zoetis Inc. For: Aug 31 Filed by: SACCARO JAMES

Wed, 02 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260902/27019663.html

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Wed, 02 Sep 2026 07:30:00 -0400

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET.

Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.

About Zoetis
Zoetis is the world’s leading animal health company, driven by

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Wed, 02 Sep 2026 07:30:00 -0400

About Zoetis
Zoetis is the world’s leading animal health company, driven by

Zoetis Inc. (ZTS) PT Lowered to $94 at TD Cowen

Tue, 25 Aug 2026 07:40:44 -0400

TD Cowen analyst Steve Scala lowered the price target on Zoetis Inc. (NYSE: ZTS) to $94.00 (from $104.00) while maintaining a Buy rating.

The analyst commented: "We lower our ZTS PT to $94 and reduce near-term 2026/27 estimates, reflecting declining clinic visits for U.S. K9 derm and parasiticides, price pressure, and competition. Our revised model assumes flat 2026 revenue and +1% EPS growth. Long-term outlook still compelling, with a projected +4% revenue and +8% EPS CAGR 2025-32, driven by OA pain, livestock, pipeline launches, and buybacks."

Zoetis Inc. (ZTS) PT Lowered to $94 at TD Cowen

Tue, 25 Aug 2026 07:40:44 -0400

TD Cowen analyst Steve Scala lowered the price target on Zoetis Inc. (NYSE: ZTS) to $94.00 (from $104.00) while maintaining a Buy rating.

Form 3 Zoetis Inc. For: Aug 17 Filed by: SACCARO JAMES

Mon, 24 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26968555.html

Form 3 Zoetis Inc. For: Aug 17 Filed by: SACCARO JAMES

Mon, 24 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26968555.html

Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates

Thu, 20 Aug 2026 07:57:41 -0400

Stifel analyst Jonathan Block lowered the price target on Zoetis Inc. (NYSE: ZTS) to $80.00 (from $85.00) while maintaining a Hold rating.

The analyst commented, "For Zoetis, “Key Franchises” are comprised of Dermatology and the Simparica Family as well as OA pain mAbs, and accounts for ~40% of 2026E total revenue. In the 10-Q, Zoetis disclosed that 2Q26 Key Franchise volume growth was down -3% y/y. This is in-line with 1Q26 (-3%), and a consistent deterioration from the levels seen in 2025. We explored Zoetis’ Key Franchise volume / price dynamic in our deep dive last week, which showed Zoetis’ Key

Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates

Thu, 20 Aug 2026 07:57:41 -0400

Stifel analyst Jonathan Block lowered the price target on Zoetis Inc. (NYSE: ZTS) to $80.00 (from $85.00) while maintaining a Hold rating.

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio
Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Thu, 13 Aug 2026 15:51:00 -0400

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio

Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax,